(VIANEWS) – Shares of Arcturus Therapeutics (NASDAQ: ARCT) dropped by a staggering 15.79% in 5 sessions from $32.36 at -15.79, to $27.25 at 15:45 EST on Thursday, after two consecutive sessions in a row of losses. NASDAQ is jumping 0.96% to $12,621.10, following the last session’s upward trend.
Arcturus Therapeutics’s last close was $28.32, 16.21% below its 52-week high of $33.80.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Arcturus Therapeutics has a trailing twelve months EPS of $0.32.
PE Ratio
Arcturus Therapeutics has a trailing twelve months price to earnings ratio of 85.16. Meaning, the purchaser of the share is investing $85.16 for every dollar of annual earnings.
More news about Arcturus Therapeutics (ARCT).
